Systemic lupus erythematosus, Lupus nephritis
CABACabaletta BioCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for Rese-cel (formerly CABA-201) in Systemic lupus erythematosus, Lupus nephritis. The expected timing is based on the latest available company guidance and may change.
06/03/26:- RESET-SLE EULAR 2026 data updated, including first two PC-free patients. Higher-dose PC-free cohorts enrolling; next readout TBA.
Verification
Confirm timing and program details against the company announcement or filing.